MPN ‘driver’ mutations result in the activation of pro‐inflammatory signalling, in particular tumour necrosis factor (TNF)/nuclear factor κ‐light‐chain‐enhancer of activated B cells (NF‐κB) pathways, in mutated HSCs and their progeny.4, 5, 6. This evidence concerns the gene TNF and myeloproliferative disorder.